I-MAB American Depositary Shares (IMAB)

I-Mab will present updated Phase 1 study data on givastomig, a bispecific antibody targeting Claudin 18.2-positive gastric cancers, at the AACR-NCI-EORTC conference in Boston in October 2025.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. B of A Securities cut the price target for Li Auto Inc. (NASDAQ: LI) from $60 to $55. B of A Securities analyst Ming Hsun Lee maintained a Buy rating. Li A...

Cancer drug developer I-Mab says a key competitor stole its research by posing as an expert witness in an arbitration proceeding.

IMab Sponsored ADR (IMAB) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

One of its phase 2 clinical trials was ended abruptly after several patients died.